Zylox-Tonbridge Medical Technology Co (HKSE:02190) Change In Working Capital : HK$0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co Change In Working Capital?

Zylox-Tonbridge Medical Technology Co's change in working capital for the quarter that ended in Dec. 2024 was HK$0.0 Mil.

Zylox-Tonbridge Medical Technology Co's change in working capital for the fiscal year that ended in Dec. 2024 was HK$-13.7 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Zylox-Tonbridge Medical Technology Co Change In Working Capital Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co Change In Working Capital Chart

Zylox-Tonbridge Medical Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-16.87

3.47

-81.00

35.85

-13.66

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Working Capital	Get a 7-Day Free Trial						-	-	-	-	-

Zylox-Tonbridge Medical Technology Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Zylox-Tonbridge Medical Technology Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zylox-Tonbridge Medical Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (HKSE:02190) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.zyloxtb.com

Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB).

Executives

Wea Enterprises, Llc	2401 A concert party to an agreement to buy shares
Zhu Hai Tong Qiao Tou Zi Zhong Xin You Xian He Huo	2401 A concert party to an agreement to buy shares
Hang Zhou Fu Jiang Tou Zi He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Zhu Hai Gui Chuang Gu Quan Tou Zi Zhong Xin You Xian He Huo	2401 A concert party to an agreement to buy shares
Hang Zhou Gui Qiao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Hang Zhou Yu Yi Hui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Zhong Shengping Sam	2401 A concert party to an agreement to buy shares
Zhao Jonathon Zhong	2501 Other
Wei Na	2501 Other
Li Zheng	2501 Other
Wang Stephen Hui	2201 Interest of corporation controlled by you
Hu Zhou Yu Yi Hui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Schroders Plc	2102 Investment manager
Highlight Medical Limited	2501 Other
Ourea Biotech Hk Limited	2501 Other

Zylox-Tonbridge Medical Technology Co Headlines

No Headlines